货号：E-T202508210001
CAS：N/A
规格：mg
纯度：≥95%
生产商：试剂家

生物活性：Nicergoline-13C,d3 is the 13C- and deuterium labeled Nicergoline. Nicergoline, an ergoline derivative ester of bromonicotinic acid, is a potent, selective and orally active antagonist of α1A-adrenoceptor. Nicergoline has vasodilator effects. Nicergoline also has ameliorative effects on cognitive function in mouse models of Alzheimer's disease[1][2].
体外研究(In Vitro)：Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[75].
试剂家 has not independently confirmed the accuracy of these methods. They are for reference only.
Nicergoline-13C,d3 相关抗体:
ADRB2 Antibody
Salbutamol Antibody (YA901)
Clenbuterol Antibody (YA904)
alpha 1a Adrenergic Receptor Antibody (YA2059)
分子量：488.40
Formula：C2313CH23D3BrN3O3
非标记 CAS：27848-84-6
中文名称：尼麦角林-13C,d3；麦角溴烟酯-13C,d3；尼什枸宁-13C,d3
运输条件：Room temperature in continental US; may vary elsewhere.
储存方式：Please store the product under the recommended conditions in the Certificate of Analysis.
纯度 & 产品资料
Data Sheet (532 KB)
产品使用指南 (1538 KB)
参考文献
[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-223.
 [Content Brief]
[2]. Alvarez-Guerra, M., N. Bertholom, and R.P. Garay, Selective blockade by nicergoline of vascular responses elicited by stimulation of alpha 1A-adrenoceptor subtype in the rat. Fundam Clin Pharmacol, 1999. 13(1): p. 50-8.
 [Content Brief]
[3]. Zang G, et, al. Ameliorative effect of nicergoline on cognitive function through the PI3K/AKT signaling pathway in mouse models of Alzheimer's disease. Mol Med Rep. 2018 May;17(5):7293-7300.
 [Content Brief]
[4]. Mizuno T, et, al. Protective effects of nicergoline against neuronal cell death induced by activated microglia and astrocytes. Brain Res. 2005 Dec 20;1066(1-2):78-85.
 [Content Brief]